ACARIZAX® approved in Canada for treatment of young children
ALK (ALKB:DC / OMX: ALK B) today announced that Health Canada has approved ALK’s ACARIZAX® tablet for use in children,...
immunotherapy
FACIT and OBIO® announce inaugural WeSEED cohort of women-led start-ups in joint seed capital and commercialization program
Program supports women entrepreneurs in life science who are driving the advancement of innovations and healthcare TORONTO, March 6, 2025...
St. Baldrick’s Foundation Awards $1.4 Million in Fellowships to Advance Childhood Cancer Research
Los Angeles, California--(Newsfile Corp. - March 6, 2025) - The St. Baldrick's Foundation, the largest charity funder of childhood cancer...
Ending heart disease with Star Trek: The Roddenberry Foundation Awards $1 Million Prize to AI company iCardio.ai
The Roddenberry Foundation is building the medically-advanced future Star Trek envisioned LOS ANGELES, March 5, 2025 /PRNewswire/ -- The Roddenberry Foundation...
Predictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro Biosciences
Predictive receives first tranche of financing to initiate integration of AI/ML platform technologies, core laboratory capabilities and business development efforts...
Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025
REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter...
Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis
Nes-Ziona, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications
Naxitamab demonstrated clinically meaningful efficacy with manageable safety in patients with relapsed/refractory high-risk neuroblastoma and residual disease in bone/bone marrowNEW...
Ultimovacs ASA: Approval and publication of prospectus
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR...
New York Blood Center Enterprises and Human Life CORD Sign Letter of Intent to Expand Manufacturing Collaboration for Umbilical Cord -Derived Mesenchymal Stromal Cells
This collaboration will expand Comprehensive Cell Solutions, a business unit of NYBCe, capabilities and geographic reach as a contract development...
Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics’ Single Cell Genomics Sequencing Technology
Gene structure information identified by combining Compugen's AI/ML predictive computational discovery platform, Unigen™ with Ultima's UG 100™ sequencing platform to better understand...
IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19
Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® technology IMNN-101 induced 2- to...
LIXTE Adds Northwestern University’s Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer
-- Lurie Cancer Center Completes Dosing of First Patient with LIXTE’s LB-100 in Combination with GSK’s Immunotherapy Dostarlimab -- PASADENA,...
MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting
Addition of AgenT-797 with Checkpoint Inhibitors, BOT/BAL, and Chemotherapy Demonstrates Robust Immune Activation, Offering Potential to Overcome Refractory Gastric CancersNEW...
PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research
Data confirms Versamune® HPV has potential as a broadly effective treatment of HPV16-associated cancers – Initiation of Phase 3 trial in...
Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC
NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology...
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara®...
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara®...
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara®...
COEPTIS’ NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus Network
The Strategic Collaboration Integrates Cutting-Edge Marketing Tools into the ValuSocial Platform, Leveraging the Robust Capabilities of Verus Coin and Blockchain...